CEO Message

Message from CEO

I would like to express my deepest gratitude to all our stakeholders, including healthcare professionals, patients, and shareholders, for their ongoing understanding and support of our business.

Since founding in 2015, we at CellSource have developed our business with a focus on regenerative medicine-related services. Regenerative medicine, particularly in the field of orthopedics, has rapidly expanded as a new treatment option, driving significant growth for the Company. Thanks to this growth and the support of our stakeholders, we were listed on the Tokyo Stock Exchange Mothers Market (now the Growth Market) in 2019 and successfully moved our listing to the Prime Market in 2023.

At the end of October 2023, Mr. Tsumamoto, the founder and then-CEO, approached me to succeed him as CEO. Initially, I hesitated, but I came to believe that it was my mission to make CellSource’s services, which hold immense social significance, a standard in society. With this conviction, I decided to accept the role of CEO.

Since assuming the position of Representative Director and CEO in January 2024, my focus has been on gaining a thorough understanding of what is happening on the ground. I have visited clinics across the country to observe how patients and doctors communicate and how operations are conducted at the front lines. I have also engaged in continuous dialogue with many doctors, nurses, and all CellSource employees. Throughout my management experience, I have always prioritized a hands-on approach with an emphasis on the frontline operations, and I will continue to uphold this approach at CellSource, ensuring that the front lines remain central to our management.

As I deepened my understanding of the business, both the strengths of CellSource and its challenges became clearer. The most significant discovery, however, was realizing that just how many people suffer from musculoskeletal pain, such as knee pain, and that their concerns are not being adequately addressed.

From this discovery, I recognized that the ultimate goal that aligns with the purpose and mission of CellSource is to wholeheartedly support patients and transform the future by freeing as many people as possible from musculoskeletal pain, allowing them to live active, vibrant lives. This is the direction we must aim for. As CEO, I see my responsibility as leading the organization in achieving this purpose, by promoting the wider adoption of regenerative medicine and expanding services that provide relief to even more people.

To continue addressing the challenges faced by more people, we must also achieve sustainable growth while consistently generating profits. To this end, we will focus on strengthening collaboration with clinics and thoroughly advancing initiatives such as strategic business streamlining and prioritization, as well as reinforcing cost discipline. Further, by launching new businesses that drive discontinuous growth, we aim to achieve sustainable growth in corporate value, backed by profitability improvements and high growth.

In order to implement various reforms going forward, we must establish an organizational structure that enables swift decision-making and business execution. To this end, as of November 1, 2024, we have strengthened our chief officer (CxO) system. Previously, decision-making authority was dispersed across multiple departments, but with the overhaul of the CxO system, we have consolidated this authority, enabling management to operate with greater urgency and speed.

I intend to fully leverage the experience and network I have accumulated thus far as a business leader, dedicating myself to ensuring that CellSource becomes the most indispensable entity for patients in the orthopedic field.

I sincerely ask our stakeholders for their continued support and guidance.